Barclays PLC Has $4.28 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Barclays PLC reduced its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 9.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 633,125 shares of the company's stock after selling 64,307 shares during the period. Barclays PLC owned approximately 0.16% of Recursion Pharmaceuticals worth $4,281,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after purchasing an additional 9,737,196 shares during the last quarter. Norges Bank bought a new position in Recursion Pharmaceuticals during the fourth quarter worth about $23,429,000. Geode Capital Management LLC grew its position in shares of Recursion Pharmaceuticals by 12.1% during the 4th quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock worth $41,160,000 after buying an additional 655,238 shares during the period. Institute for Wealth Management LLC. bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $3,928,000. Finally, Platinum Investment Management Ltd. raised its position in shares of Recursion Pharmaceuticals by 293.9% in the 4th quarter. Platinum Investment Management Ltd. now owns 733,011 shares of the company's stock valued at $4,955,000 after acquiring an additional 546,929 shares during the period. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock opened at $5.73 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -3.75 and a beta of 1.00. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The stock's 50-day moving average is $6.21 and its 200-day moving average is $6.78.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company's revenue was down 57.8% compared to the same quarter last year. During the same period last year, the company earned ($0.42) EPS. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on RXRX. Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Morgan Stanley dropped their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Finally, KeyCorp decreased their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $8.20.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.